GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan.
UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium bromide and a long-acting beta2 agonist (LABA) vilanterol (VI), administered using the Ellipta inhaler.
The investigational once-daily LAMA/LABA combination medicine UMEC/VI is developed for patients with chronic obstructive pulmonary disease (COPD).
A new drug application has been submitted as a maintenance bronchodilator treatment to relieve symptoms of obstructive airway disorder coupled with COPD.
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/gsk-theravance-submit-anoro-ellipta-regulatory-application-in-japan-250413
